Polymorphism discovery in 51 chemotherapy pathway genes.

Authors:
Robert R Freimuth
Robert R Freimuth
Mayo Clinic
United States
Ming Xiao
Ming Xiao
Nanjing Medical University
China
Sharon Marsh
Sharon Marsh
Washington University School of Medicine
United States
Matthew Minton
Matthew Minton
Washington University School of Medicine
United States
Nicholas Addleman
Nicholas Addleman
Washington University School of Medicine
United States
Howard L McLeod
Howard L McLeod
University of North Carolina
United States
Pui-Yan Kwok
Pui-Yan Kwok
University of California
United States

Hum Mol Genet 2005 Dec 20;14(23):3595-603. Epub 2005 Oct 20.

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Candidate gene pharmacogenetic studies offer a strategy for the rapid assessment of putative predictive markers. As a first step toward studying the pharmacogenetics of cancer chemotherapy, 51 candidate genes from the pathways of antineoplastic agents were resequenced to identify common genetic polymorphisms that might alter therapeutic response or toxicity. Forty DNA samples were screened from each of three population groups: African-Americans, Asian-Americans and European-Americans. Nearly 378 kb of genomic sequence was obtained from each sample. Nine hundred and four variants were identified, including 139 coding single nucleotide polymorphisms (cSNPs). Three hundred and fifty-six (40%) polymorphisms were common to all three populations and 366 (41%) were population specific. Three hundred and forty-six (38%) variants were novel polymorphisms that were not present in the three public databases that were examined. One hundred and eleven (35%) of the 319 non-synonymous cSNPs that were identified by either resequencing or database mining were predicted by PolyPhen to be either possibly or probably damaging. For the non-synonymous cSNPs identified by resequencing, both the number of cSNPs found and the maximum estimated allele frequency decreased with increasing predicted severity. These results provide experimental validation and estimated allele frequencies for polymorphisms in three common ethnic groups and facilitate applied pharmacogenetic studies of anticancer drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/ddi387DOI Listing
December 2005
5 Reads

Publication Analysis

Top Keywords

pharmacogenetic studies
8
csnps identified
8
polymorphisms three
8
estimated allele
8
identified resequencing
8
non-synonymous csnps
8
three
6
polymorphisms
5
38% variants
4
frequency decreased
4
african-americans asian-americans
4
european-americans 378
4
genomic sequence
4
mining predicted
4
378 genomic
4
forty-six 38%
4
allele frequency
4
groups african-americans
4
asian-americans european-americans
4
three population
4

Altmetric Statistics

Similar Publications

Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.

Pharmacogenetics 2001 Dec;11(9):747-56

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School-Mayo Medical School-Mayo Clinic, Rochester MN, USA.

Sulfotransferase (SULT) enzymes catalyze an important phase II reaction in the biotransformation of many drugs and other xenobiotics. We previously cloned the human SULT1C1 cDNA and gene as steps toward pharmacogenetic studies. We have now 'resequenced' the exons, portions of introns flanking exons and approximately 315 bp of the 5' flanking region of SULT1C1 in 89 DNA samples from Caucasian subjects to identify common genetic polymorphisms. Read More

View Article
December 2001

Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics.

Pharmacogenet Genomics 2006 Apr;16(4):265-77

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

5,10-Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in the folate metabolic pathway. Common genetic polymorphisms in the human MTHFR gene are associated with individual variation in the efficacy and toxicity of chemotherapeutic agents, such as methotrexate and 5-fluorouracil. However, the full range of polymorphisms and intragene haplotypes in the human MTHFR gene remains unclear. Read More

View Article
April 2006

Single nucleotide polymorphisms in bone turnover-related genes in Koreans: ethnic differences in linkage disequilibrium and haplotype.

BMC Med Genet 2007 Nov 26;8:70. Epub 2007 Nov 26.

Center for Genome Science, National Institute of Health, 5 Nokbun-dong, Eunpyung-gu, Seoul 122-701, Republic of Korea.

Background: Osteoporosis is defined as the loss of bone mineral density that leads to bone fragility with aging. Population-based case-control studies have identified polymorphisms in many candidate genes that have been associated with bone mass maintenance or osteoporotic fracture. To investigate single nucleotide polymorphisms (SNPs) that are associated with osteoporosis, we examined the genetic variation among Koreans by analyzing 81 genes according to their function in bone formation and resorption during bone remodeling. Read More

View Article
November 2007

Single-nucleotide polymorphisms in genes relating to homocysteine metabolism: how applicable are public SNP databases to a typical European population?

Eur J Hum Genet 2005 Jan;13(1):86-95

Institute of Inherited Metabolic Disorders, Charles University, 1st Faculty of Medicine, Prague, Czech Republic.

To facilitate the association studies in complex diseases characterized by hyperhomocysteinemia, we collected structural and frequency data on single-nucleotide polymorphism (SNPs) in 24 genes relating to homocysteine metabolism. Firstly, we scanned approximately 1.2 Mbp of sequence in the NCBI SNP database (dbSNP) build 110 and we detected 1353 putative SNPs with an average in silico genic density of 1:683. Read More

View Article
January 2005